EGFR and breast adenocarcinoma: Similarly, gemcitabine-(C4-amide)-[anti-EGFR] produced measurably higher levels of canti-neoplastic cytotoxicity when incubated with chemotherapeutic-resistant mammary adenocarcinoma (SKBr-3) for direct contact periods of 182-hours compared to 96-hours (Figure 5 and Figure 6).